Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors (EXCEL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00579254|
Recruitment Status : Terminated (See the termination reason in detailed description.)
First Posted : December 24, 2007
Results First Posted : June 19, 2009
Last Update Posted : June 25, 2009
|Condition or disease||Intervention/treatment||Phase|
|Hypertension and Cardiovascular Risk Factors||Drug: CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)||Phase 4|
Patients who have been prescribed single pill Caduet are eligible to participate in this study. The treating physician will obtain written informed consent from each subject or the subject's legally acceptable representative before any study-specific activity is performed.
The study terminated on May 5, 2008. The decision to terminate was due to inability to achieve study timelines and undue delay in obtaining IEC/IRB permission at some sites. No safety or efficacy issues caused the decision to terminate.
|Study Type :||Observational|
|Actual Enrollment :||112 participants|
|Official Title:||Real Life Experience With Caduet Evaluating Effectiveness, Safety and Tolerability in the Management of Cardiovascular Risk Factors (EXCEL Study)|
|Study Start Date :||December 2007|
|Primary Completion Date :||May 2008|
|Study Completion Date :||May 2008|
Drug: CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Change in Systolic and Diastolic Blood Pressure [ Time Frame: Baseline, 24 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00579254
|Study Director:||Pfizer CT.gov Call Center||Pfizer|